Combining Microneedles and Electrical Current Delivers KPV Peptide Through the Skin

In vitro permeation study using dermatomed (thickness-controlled) human skin. Researchers tested four delivery approaches: passive diffusion, microneedle pre-treatment alone, iontophoresis alone, and microneedles plus iontophoresis combined. They varied current strength, KPV concentration, and duration. Permeation and skin retention were quantified, and confocal microscopy with fluorescently-labeled KPV was used to visualize penetration depth.

KPV is a potent anti-inflammatory peptide, but like most peptides, it can't cross the skin barrier on its own — making injection the only option. This study demonstrates a path toward needle-free KPV delivery through the skin using microneedles and electrical current. If this approach translates to clinical use, it could make KPV accessible as a topical anti-inflammatory treatment.

Peptide drug delivery is one of the biggest challenges in pharmaceutical science — most peptides are destroyed in the stomach or can't cross biological barriers. Transdermal delivery is an attractive alternative to injection, especially for locally-acting anti-inflammatory peptides like KPV. This study contributes to a growing body of work showing that combination enhancement strategies (microneedles + iontophoresis) can overcome the skin barrier for peptide delivery.

This is an in vitro study using excised human skin — it does not account for blood flow, immune responses, or systemic absorption that would occur in living tissue. No animal or human in vivo testing was performed. The anti-inflammatory effect of the delivered KPV was not measured — only the physical delivery was assessed. Long-term skin safety of repeated iontophoresis and microneedling was not evaluated.